WuXi AppTec Non-GAAP EPS of RMB 6.21, revenue of RMB 45.54B; rasies full-year guidance

WuXi AppTec, a leading Chinese biotech firm, has raised its full-year revenue outlook following a remarkable surge in profits. In the first nine months of 2026, the company's net profit skyrocketed by 62.4 percent to 19.16 billion yuan (US$2.87 billion), while revenue grew by 38.6 percent to 45.54 billion yuan, driven by robust demand for its drug development and manufacturing services.

Net profit for the full year was now anticipated to reach between 61 billion yuan and 61.9 billion yuan, up from the previous forecast of 58.5 billion yuan to 60.5 billion yuan. The Shanghai-based company also raised its expectations for revenue from continuing operations to grow 40 to 42 percent. WuXi AppTec's chemistry segment, the largest contributor, saw year-on-year revenue growth of 51.5 percent to 39.36 billion yuan in the first three quarters of 2026.

Revenue from small-molecule drug development and manufacturing services surged 65.6 percent to 23.58 billion yuan during the same period. The biology business expanded by 12.4 percent to 2.19 billion yuan. The company has been accelerating capacity planning to meet the increasing customer demand, including bringing a new site in Changzhou online earlier than planned.

WuXi AppTec increased its full-year adjusted free cash flow forecast to 14.5 billion to 15.5 billion yuan, up from 13.5 billion to 14.5 billion yuan, and raised its capital expenditure forecast to 8 billion to 8.5 billion yuan. Despite facing scrutiny from Washington, with the U.S. Department of Defence listing the company among its Chinese military companies in June, WuXi AppTec shares closed 1.2 percent higher on Monday.